164 related articles for article (PubMed ID: 1979176)
1. Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease.
Close SP; Elliott PJ; Hayes AG; Marriott AS
Psychopharmacology (Berl); 1990; 102(3):295-300. PubMed ID: 1979176
[TBL] [Abstract][Full Text] [Related]
2. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Nomoto M; Jenner P; Marsden CD
Neurosci Lett; 1985 Jun; 57(1):37-41. PubMed ID: 3162113
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
Elliott PJ; Walsh DM; Close SP
Neurosci Lett; 1992 Aug; 142(1):1-4. PubMed ID: 1357609
[TBL] [Abstract][Full Text] [Related]
4. Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Close SP; Marriott AS; Pay S
Br J Pharmacol; 1985 Jun; 85(2):320-2. PubMed ID: 3928007
[TBL] [Abstract][Full Text] [Related]
5. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Gnanalingham KK; Erol DD; Hunter AJ; Smith LA; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(3):275-86. PubMed ID: 7770603
[TBL] [Abstract][Full Text] [Related]
6. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Grondin R; Bédard PJ; Britton DR; Shiosaki K
Neurology; 1997 Aug; 49(2):421-6. PubMed ID: 9270571
[TBL] [Abstract][Full Text] [Related]
7. Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
Kuno S
Eur Neurol; 1997; 38 Suppl 1():18-22. PubMed ID: 9276196
[TBL] [Abstract][Full Text] [Related]
8. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
[TBL] [Abstract][Full Text] [Related]
9. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
[TBL] [Abstract][Full Text] [Related]
10. The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958.
Andringa G; Lubbers L; Drukarch B; Stoof JC; Cools AR
Behav Pharmacol; 1999 Mar; 10(2):175-82. PubMed ID: 10780830
[TBL] [Abstract][Full Text] [Related]
11. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
12. MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects.
Jenner P; Rose S; Nomoto M; Marsden CD
Adv Neurol; 1987; 45():183-6. PubMed ID: 2881443
[No Abstract] [Full Text] [Related]
13. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
14. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
15. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
16. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.
Steece-Collier K; Chambers LK; Jaw-Tsai SS; Menniti FS; Greenamyre JT
Exp Neurol; 2000 May; 163(1):239-43. PubMed ID: 10785463
[TBL] [Abstract][Full Text] [Related]
17. NMSP binding to dopamine and serotonin receptors in MPTP-induced parkinsonism: relation to dopa therapy.
Borbely K; Brooks RA; Wong DF; Burns RS; Cumming P; Gjedde A; Di Chiro G
Acta Neurol Scand; 1999 Jul; 100(1):42-52. PubMed ID: 10416511
[TBL] [Abstract][Full Text] [Related]
18. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Riahi G; Morissette M; Parent M; Di Paolo T
Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
[TBL] [Abstract][Full Text] [Related]
19. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.
Gnanalingham KK; Hunter AJ; Jenner P; Marsden CD
Psychopharmacology (Berl); 1995 Feb; 117(3):287-97. PubMed ID: 7770604
[TBL] [Abstract][Full Text] [Related]
20. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
